Objective: To evaluate the impact of anti-TNF therapy on CV risk markers and surrogate indicators of subclinical atherosclerosis in patients with AS, and to examine the influence of modifiable lifestyle factors such as smoking, physical activity, and body mass index (BMI) on CV outcomes. Here, TNF is linked to atherosclerosis.